R-H. Xu

1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)

R-H. Xu, F. Wang, Chengxu Cui et al. · Annals of Oncology · 2021 · 24 citations

Medicine, Oncology, Pharmacology +13

LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

R-H. Xu, D-Y. Oh, Ken Kato et al. · Annals of Oncology · 2023 · 16 citations

Medicine, Oncology, Pharmacology +13

550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study

R-H. Xu, Ye Xu, Dongyao Yan et al. · Annals of Oncology · 2023 · 14 citations · Full text

Medicine, Oncology, Pharmacology +11

860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma

Fei Han, Fei Wang, Y-R. Shi et al. · Annals of Oncology · 2023 · 12 citations · Full text

Medicine, Oncology, Pharmacology +13

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

Kohei Shitara, S-E. Al-Batran, Y-J. Bang et al. · Annals of Oncology · 2020 · 11 citations · Full text

Medicine, Oncology, Pharmacotherapy +13